Literature DB >> 11896931

Human cytomegalovirus (HCMV)-infected endothelial cells and macrophages are less susceptible to natural killer lysis independent of the downregulation of classical HLA class I molecules or expression of the HCMV class I homologue, UL18.

J Odeberg1, C Cerboni, H Browne, K Kärre, E Möller, E Carbone, C Söderberg-Nauclér.   

Abstract

A number of reports have suggested that human cytomegalovirus (HCMV)-infected fibroblasts are resistant to natural killer (NK) lysis, and that the HCMV-encoded human leucocyte antigen (HLA) class I homologue UL18 may be responsible for this effect. While fibroblasts are easy to infect in vitro, their role in HCMV pathogenesis in vivo is unclear. Here, we have established systems to address NK recognition of infected endothelial cells and macrophages, two important HCMV cellular reservoirs in vivo. The HCMV-infected endothelial cells exhibited increased resistance to NK killing, and, in most experiments, infected macrophages demonstrated a decreased susceptibility to NK lysis. Infection with the mutant HCMV strain RV670, lacking the genes US1-9 and US11 that are responsible for downregulation of HLA class I molecules, also led to decreased NK susceptibility. Furthermore, reduced NK susceptibility was independent of the expression of the HLA class I homologue UL18, since cells infected with the UL18Delta HCMV strain were also less susceptible to NK killing. These results suggest that HCMV-induced resistance to NK cytotoxicity in endothelial cells and macrophages is independent of known pathways that interfere with the expression of cellular HLA class I A, B and C surface antigens and the HCMV encoded class I homologue UL18.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896931     DOI: 10.1046/j.1365-3083.2002.01025.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Human cytomegalovirus infection of M1 and M2 macrophages triggers inflammation and autologous T-cell proliferation.

Authors:  Carina Bayer; Stefania Varani; Li Wang; Paul Walther; Shaoxia Zhou; Sarah Straschewski; Max Bachem; Cecilia Söderberg-Naucler; Thomas Mertens; Giada Frascaroli
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

2.  The human cytomegalovirus protein UL16 mediates increased resistance to natural killer cell cytotoxicity through resistance to cytolytic proteins.

Authors:  Jenny Odeberg; Helena Browne; Sunil Metkar; Christopher J Froelich; Lars Brandén; David Cosman; Cecilia Söderberg-Nauclér
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

3.  Genetic variability of the major histocompatibility complex class I homologue encoded by human cytomegalovirus leads to differential binding to the inhibitory receptor ILT2.

Authors:  Mar Valés-Gómez; Mitsunori Shiroishi; Katsumi Maenaka; Hugh T Reyburn
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  Feeling manipulated: cytomegalovirus immune manipulation.

Authors:  Mindy Miller-Kittrell; Tim E Sparer
Journal:  Virol J       Date:  2009-01-09       Impact factor: 4.099

5.  The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells.

Authors:  Virginie Prod'homme; Cora Griffin; Rebecca J Aicheler; Eddie C Y Wang; Brian P McSharry; Carole R Rickards; Richard J Stanton; Leszek K Borysiewicz; Miguel López-Botet; Gavin W G Wilkinson; Peter Tomasec
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

6.  Characterization of a highly glycosylated form of the human cytomegalovirus HLA class I homologue gpUL18.

Authors:  Cora Griffin; Eddie C Y Wang; Brian P McSharry; Carole Rickards; Helena Browne; Gavin W G Wilkinson; Peter Tomasec
Journal:  J Gen Virol       Date:  2005-11       Impact factor: 3.891

Review 7.  Dendritic cell biology in human cytomegalovirus infection and the clinical consequences for host immunity and pathology.

Authors:  Sara Gredmark-Russ; Cecilia Söderberg-Nauclér
Journal:  Virulence       Date:  2012-10-17       Impact factor: 5.882

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.